4D Molecular Therapeutics (Nasdaq: FDMT) has announced the granting of employment inducement awards to eight new non-executive employees. On May 13, 2025, the company's compensation committee approved the issuance of 31,800 Restricted Stock Units (RSUs) under its 2025 Employment Inducement Award Plan. This plan was established in February 2025 and approved by the board of directors in compliance with Nasdaq Global Market Rule 5635(c)(4), which specifically allows for equity grants as employment inducements for new hires.
4D Molecular Therapeutics (Nasdaq: FDMT) ha annunciato la concessione di premi di incentivo all'assunzione a otto nuovi dipendenti non esecutivi. Il 13 maggio 2025, il comitato per la remunerazione della società ha approvato l'emissione di 31.800 Unità Azionarie Vincolate (RSU) nell'ambito del suo Piano di Premi di Incentivo all'Assunzione 2025. Questo piano è stato istituito a febbraio 2025 ed è stato approvato dal consiglio di amministrazione in conformità con la Regola 5635(c)(4) del Nasdaq Global Market, che consente specificamente l'assegnazione di azioni come incentivi all'assunzione per nuovi dipendenti.
4D Molecular Therapeutics (Nasdaq: FDMT) ha anunciado la concesión de premios de incentivo por contratación a ocho nuevos empleados no ejecutivos. El 13 de mayo de 2025, el comité de compensación de la empresa aprobó la emisión de 31,800 Unidades de Acciones Restringidas (RSU) bajo su Plan de Premios de Incentivo por Contratación 2025. Este plan fue establecido en febrero de 2025 y aprobado por la junta directiva en cumplimiento con la Regla 5635(c)(4) del Nasdaq Global Market, que permite específicamente concesiones de acciones como incentivos por contratación para nuevos empleados.
4D Molecular Therapeutics(Nasdaq: FDMT)는 8명의 새로운 비임원 직원에게 고용 유도 보상을 부여했다고 발표했습니다. 2025년 5월 13일, 회사의 보상 위원회는 2025년 고용 유도 보상 계획에 따라 31,800개의 제한 주식 단위(RSU) 발행을 승인했습니다. 이 계획은 2025년 2월에 설립되었으며, 신규 채용에 대한 주식 부여를 허용하는 Nasdaq 글로벌 마켓 규칙 5635(c)(4)를 준수하여 이사회에서 승인되었습니다.
4D Molecular Therapeutics (Nasdaq : FDMT) a annoncé l'attribution de primes d'incitation à l'emploi à huit nouveaux employés non cadres. Le 13 mai 2025, le comité de rémunération de la société a approuvé l'émission de 31 800 unités d'actions restreintes (RSU) dans le cadre de son Plan d'Attribution d'Incitation à l'Emploi 2025. Ce plan a été établi en février 2025 et approuvé par le conseil d'administration conformément à la règle 5635(c)(4) du Nasdaq Global Market, qui autorise spécifiquement les attributions d'actions comme incitations à l'embauche de nouveaux employés.
4D Molecular Therapeutics (Nasdaq: FDMT) hat die Gewährung von Anreizprämien für die Einstellung von acht neuen nicht geschäftsführenden Mitarbeitern bekannt gegeben. Am 13. Mai 2025 genehmigte der Vergütungsausschuss des Unternehmens die Ausgabe von 31.800 Restricted Stock Units (RSUs) im Rahmen seines 2025 Employment Inducement Award Plans. Dieser Plan wurde im Februar 2025 eingeführt und vom Vorstand gemäß der Nasdaq Global Market Regel 5635(c)(4) genehmigt, die ausdrücklich Aktienzuteilungen als Anreize für Neueinstellungen erlaubt.
Positive
None.
Negative
None.
EMERYVILLE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 13, 2025, the compensation committee of the Company’s board of directors granted eight new non-executive employees 31,800 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Our lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Our lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. Our second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
How many RSUs did 4D Molecular Therapeutics (FDMT) grant to new employees in May 2025?
4DMT granted 31,800 Restricted Stock Units (RSUs) to eight new non-executive employees on May 13, 2025.
What is the purpose of FDMT's 2025 Employment Inducement Award Plan?
The plan was established to provide equity grants as employment inducements to attract new employees to join 4D Molecular Therapeutics, in accordance with Nasdaq Global Market rules.
When was FDMT's 2025 Employment Inducement Award Plan approved?
The Employment Inducement Award Plan was approved by 4DMT's board of directors in February 2025.
Which Nasdaq rule allows FDMT to grant these inducement awards?
The grants were made under Rule 5635(c)(4) of The Nasdaq Global Market, which permits equity grants as employment inducements for new hires.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
